These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35524286)

  • 1. Growth differentiation factor 11 induces skeletal muscle atrophy via a STAT3-dependent mechanism in pulmonary arterial hypertension.
    Xiang G; Ying K; Jiang P; Jia M; Sun Y; Li S; Wu X; Hao S
    Skelet Muscle; 2022 May; 12(1):10. PubMed ID: 35524286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathophysiological levels of GDF11 activate Smad2/Smad3 signaling and induce muscle atrophy in human iPSC-derived myocytes.
    Honda M; Makino T; Zhao X; Matsuto M; Sakurai H; Takahashi Y; Shimizu M; Sato R; Yamauchi Y
    Am J Physiol Cell Physiol; 2022 Nov; 323(5):C1402-C1409. PubMed ID: 36094432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic targeting of GDF11 in muscle atrophy: Insights and strategies.
    Wang C; Liu X; Hu X; Wu T; Duan R
    Int J Biol Macromol; 2024 Nov; 279(Pt 3):135321. PubMed ID: 39236952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A GDF11/myostatin inhibitor, GDF11 propeptide-Fc, increases skeletal muscle mass and improves muscle strength in dystrophic mdx mice.
    Jin Q; Qiao C; Li J; Xiao B; Li J; Xiao X
    Skelet Muscle; 2019 May; 9(1):16. PubMed ID: 31133057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DA-Raf and the MEK inhibitor trametinib reverse skeletal myocyte differentiation inhibition or muscle atrophy caused by myostatin and GDF11 through the non-Smad Ras-ERK pathway.
    Masuzawa R; Takahashi K; Takano K; Nishino I; Sakai T; Endo T
    J Biochem; 2022 Jan; 171(1):109-122. PubMed ID: 34676394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth/differentiation factor 15 causes TGFβ-activated kinase 1-dependent muscle atrophy in pulmonary arterial hypertension.
    Garfield BE; Crosby A; Shao D; Yang P; Read C; Sawiak S; Moore S; Parfitt L; Harries C; Rice M; Paul R; Ormiston ML; Morrell NW; Polkey MI; Wort SJ; Kemp PR
    Thorax; 2019 Feb; 74(2):164-176. PubMed ID: 30554141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth Differentiation Factor 11 Promotes Abnormal Proliferation and Angiogenesis of Pulmonary Artery Endothelial Cells.
    Yu X; Chen X; Zheng XD; Zhang J; Zhao X; Liu Y; Zhang H; Zhang L; Yu H; Zhang M; Ma C; Hao X; Zhu D
    Hypertension; 2018 Apr; 71(4):729-741. PubMed ID: 29463625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exogenous GDF11 induces cardiac and skeletal muscle dysfunction and wasting.
    Zimmers TA; Jiang Y; Wang M; Liang TW; Rupert JE; Au ED; Marino FE; Couch ME; Koniaris LG
    Basic Res Cardiol; 2017 Jul; 112(4):48. PubMed ID: 28647906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effects of growth differentiation factor 11 on autophagy deficiency-induced dedifferentiation of arterial smooth muscle cells.
    Yuan X; Bhat OM; Lohner H; Li N; Zhang Y; Li PL
    Am J Physiol Heart Circ Physiol; 2019 Feb; 316(2):H345-H356. PubMed ID: 30462553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of GDF11 in aging and skeletal muscle, cardiac and bone homeostasis.
    Egerman MA; Glass DJ
    Crit Rev Biochem Mol Biol; 2019 Apr; 54(2):174-183. PubMed ID: 31144559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GDF11 Increases with Age and Inhibits Skeletal Muscle Regeneration.
    Egerman MA; Cadena SM; Gilbert JA; Meyer A; Nelson HN; Swalley SE; Mallozzi C; Jacobi C; Jennings LL; Clay I; Laurent G; Ma S; Brachat S; Lach-Trifilieff E; Shavlakadze T; Trendelenburg AU; Brack AS; Glass DJ
    Cell Metab; 2015 Jul; 22(1):164-74. PubMed ID: 26001423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GDF11 does not improve the palmitate induced insulin resistance in C2C12.
    Jing YY; Li D; Wu F; Gong LL; Li R
    Eur Rev Med Pharmacol Sci; 2017 Apr; 21(8):1795-1802. PubMed ID: 28485800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neonatal Systemic AAV-Mediated Gene Delivery of GDF11 Inhibits Skeletal Muscle Growth.
    Jin Q; Qiao C; Li J; Li J; Xiao X
    Mol Ther; 2018 Apr; 26(4):1109-1117. PubMed ID: 29503194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Supraphysiological levels of GDF11 induce striated muscle atrophy.
    Hammers DW; Merscham-Banda M; Hsiao JY; Engst S; Hartman JJ; Sweeney HL
    EMBO Mol Med; 2017 Apr; 9(4):531-544. PubMed ID: 28270449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sepsis induces interleukin 6, gp130/JAK2/STAT3, and muscle wasting.
    Zanders L; Kny M; Hahn A; Schmidt S; Wundersitz S; Todiras M; Lahmann I; Bandyopadhyay A; Wollersheim T; Kaderali L; Luft FC; Birchmeier C; Weber-Carstens S; Fielitz J
    J Cachexia Sarcopenia Muscle; 2022 Feb; 13(1):713-727. PubMed ID: 34821076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Supraphysiologic Administration of GDF11 Induces Cachexia in Part by Upregulating GDF15.
    Jones JE; Cadena SM; Gong C; Wang X; Chen Z; Wang SX; Vickers C; Chen H; Lach-Trifilieff E; Hadcock JR; Glass DJ
    Cell Rep; 2018 Feb; 22(6):1522-1530. PubMed ID: 29425507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of heat shock protein (HSP) 90 reverses signal transducer and activator of transcription (STAT) 3-mediated muscle wasting in cancer cachexia mice.
    Niu M; Song S; Su Z; Wei L; Li L; Pu W; Zhao C; Ding Y; Wang J; Cao W; Gao Q; Wang H
    Br J Pharmacol; 2021 Nov; 178(22):4485-4500. PubMed ID: 34265073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imperatorin alleviates cancer cachexia and prevents muscle wasting via directly inhibiting STAT3.
    Chen L; Xu W; Yang Q; Zhang H; Wan L; Xin B; Zhang J; Guo C
    Pharmacol Res; 2020 Aug; 158():104871. PubMed ID: 32413482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GDF11 promotes osteogenesis as opposed to MSTN, and follistatin, a MSTN/GDF11 inhibitor, increases muscle mass but weakens bone.
    Suh J; Kim NK; Lee SH; Eom JH; Lee Y; Park JC; Woo KM; Baek JH; Kim JE; Ryoo HM; Lee SJ; Lee YS
    Proc Natl Acad Sci U S A; 2020 Mar; 117(9):4910-4920. PubMed ID: 32071240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.
    Bonetto A; Aydogdu T; Jin X; Zhang Z; Zhan R; Puzis L; Koniaris LG; Zimmers TA
    Am J Physiol Endocrinol Metab; 2012 Aug; 303(3):E410-21. PubMed ID: 22669242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.